Sawai Group Holdings Co., Ltd. (4887.T)
JPY 2033.5
(-1.09%)
JPY 2033.5
(-1.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 163.99 Billion JPY | 8.3% |
| 2022 | 151.42 Billion JPY | 1.34% |
| 2021 | 149.41 Billion JPY | -2.08% |
| 2020 | 152.59 Billion JPY | 0.97% |
| 2019 | 151.12 Billion JPY | 0.97% |
| 2018 | 149.68 Billion JPY | -4.06% |
| 2017 | 156.01 Billion JPY | 84.91% |
| 2016 | 84.37 Billion JPY | 4.46% |
| 2015 | 80.77 Billion JPY | 50.18% |
| 2014 | 53.78 Billion JPY | 11.93% |
| 2013 | 48.04 Billion JPY | -27.6% |
| 2012 | 66.36 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 158.99 Billion JPY | -3.05% |
| 2023 FY | 163.99 Billion JPY | 8.3% |
| 2023 Q1 | 169.96 Billion JPY | 12.24% |
| 2023 Q2 | 171.27 Billion JPY | 0.77% |
| 2023 Q4 | 163.99 Billion JPY | -5.18% |
| 2023 Q3 | 172.95 Billion JPY | 0.98% |
| 2022 Q1 | 158.02 Billion JPY | 5.76% |
| 2022 FY | 151.42 Billion JPY | 1.34% |
| 2022 Q4 | 151.42 Billion JPY | -2.1% |
| 2022 Q3 | 154.67 Billion JPY | -7.81% |
| 2022 Q2 | 167.78 Billion JPY | 6.17% |
| 2021 Q2 | 150.1 Billion JPY | 1.15% |
| 2021 Q1 | 148.39 Billion JPY | -2.75% |
| 2021 FY | 149.41 Billion JPY | -2.08% |
| 2021 Q4 | 149.41 Billion JPY | -3.27% |
| 2021 Q3 | 154.47 Billion JPY | 2.91% |
| 2020 Q1 | 148.08 Billion JPY | -2.01% |
| 2020 FY | 152.59 Billion JPY | 0.97% |
| 2020 Q4 | 152.59 Billion JPY | 0.72% |
| 2020 Q2 | 150.57 Billion JPY | 1.68% |
| 2020 Q3 | 151.5 Billion JPY | 0.61% |
| 2019 Q3 | 154.92 Billion JPY | 0.47% |
| 2019 Q1 | 152.13 Billion JPY | 1.63% |
| 2019 Q2 | 154.2 Billion JPY | 1.36% |
| 2019 Q4 | 151.12 Billion JPY | -2.45% |
| 2019 FY | 151.12 Billion JPY | 0.97% |
| 2018 Q3 | 153.69 Billion JPY | 2.88% |
| 2018 FY | 149.68 Billion JPY | -4.06% |
| 2018 Q4 | 149.68 Billion JPY | -2.61% |
| 2018 Q2 | 149.39 Billion JPY | -2.39% |
| 2018 Q1 | 153.05 Billion JPY | -1.9% |
| 2017 Q4 | 156.01 Billion JPY | -9.92% |
| 2017 FY | 156.01 Billion JPY | 84.91% |
| 2017 Q1 | 214.84 Billion JPY | 155.95% |
| 2017 Q2 | 201.77 Billion JPY | -6.09% |
| 2017 Q3 | 173.19 Billion JPY | -14.16% |
| 2016 Q3 | 79.46 Billion JPY | -5.36% |
| 2016 Q2 | 83.96 Billion JPY | -2.52% |
| 2016 FY | 84.37 Billion JPY | 4.46% |
| 2016 Q4 | 83.94 Billion JPY | 5.63% |
| 2016 Q1 | 86.13 Billion JPY | 6.64% |
| 2015 Q2 | 67.12 Billion JPY | 6.3% |
| 2015 FY | 80.77 Billion JPY | 50.18% |
| 2015 Q4 | 80.77 Billion JPY | 2.27% |
| 2015 Q3 | 78.97 Billion JPY | 17.66% |
| 2015 Q1 | 63.14 Billion JPY | 17.41% |
| 2014 Q1 | 44.58 Billion JPY | -7.22% |
| 2014 Q2 | 51.43 Billion JPY | 15.37% |
| 2014 Q3 | 52.72 Billion JPY | 2.52% |
| 2014 Q4 | 53.78 Billion JPY | 2.0% |
| 2014 FY | 53.78 Billion JPY | 11.93% |
| 2013 FY | 48.04 Billion JPY | -27.6% |
| 2013 Q4 | 48.04 Billion JPY | 20.07% |
| 2013 Q3 | 40.01 Billion JPY | -29.11% |
| 2013 Q2 | 56.44 Billion JPY | -14.88% |
| 2013 Q1 | 66.31 Billion JPY | -0.08% |
| 2012 Q3 | 68.95 Billion JPY | 1.99% |
| 2012 Q4 | 66.36 Billion JPY | -3.75% |
| 2012 Q2 | 67.6 Billion JPY | 0.0% |
| 2012 FY | 66.36 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | -556.291% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 97.907% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 78.174% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 0.219% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -4730.486% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | -282.556% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | -488.509% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 66.858% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -3153.849% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | -165.818% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | -431.895% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | -312.107% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | -427.583% |
| Tsumura & Co. | 132.88 Billion JPY | -23.41% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | -312.138% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | -1133.316% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 40.313% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | -271.38% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | -131.942% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | -249.72% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -2241.768% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | -544.656% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | -1914.14% |
| MedRx Co., Ltd | 129 Million JPY | -127027.132% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -4911.222% |
| Solasia Pharma K.K. | 673 Million JPY | -24267.608% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -25305.614% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | -422.59% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -16115.516% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 68.703% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -2258.832% |